Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand Disease
Phase of Trial: Phase IV
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Grifols
- 06 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Apr 2020.
- 06 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2020.
- 24 Dec 2013 New trial record